Physician profile
Christopher D Dingess
NPI 1982016192
$9,580.15
in general payments reported to CMS, 2019-2025
51 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $823 · 2021: $1,468 · 2022: $1,461 · 2023: $1,868 · 2024: $1,571 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,501.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,286.57 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $944.14 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $935.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $817.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.91 | 2019-2025 | Jardiance |
| Pfizer INC. | $531.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $516.63 | 2020-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $452.80 | 2021-2024 | |
| Abbott Laboratories | $295.83 | 2021-2025 | Freestyle Libre 2, Proclaim, Freestyle Libre 3 |
| Daiichi Sankyo INC. | $264.83 | 2019-2023 | Injectafer |
| Amgen INC. | $235.76 | 2019-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $197.80 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $165.05 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $143.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $142.45 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dingess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.